Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-114 + Capecitabine in Advanced Solid Tumors
NCT02025803Phase 1Completed
- Sponsor
- Taiho Oncology
- Start
- Nov 2012
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS-114 in solid tumor (advanced stage), breast cancer and colorectal cancer (CRC), sponsored by Taiho Oncology. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Nov 2012; status: completed.
02
Drugs
TAS-114
03
Conditions
solid tumor (advanced stage)breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02025803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025803.